LCM
WHWK

Lynx1 Capital Management’s Whitehawk Therapeutics WHWK Stock Holding History

Lynx1 Capital Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-64,739
Closed -$831K – 14
2022
Q4 		$831K Buy
+64,739
New +$845K 0.72% 12

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Lynx1 Capital Management's WHWK Position: Q1 2023 in Review

Lynx1 Capital Management sold out of Whitehawk Therapeutics (WHWK) in Q1 2023, closing a stake of 64,739 shares — an estimated $831K sold.

Lynx1 Capital Management first reported a position in WHWK in Q4 2022 and held it in 1 quarter. The position peaked at $831K in Q4 2022. 70 funds tracked by Wall St. Rank hold WHWK as of Q1 2023.

  • Lynx1 Capital Management reported no remaining Whitehawk Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Lynx1 Capital Management sold 64,739 Whitehawk Therapeutics shares in Q1 2023, an estimated $831K.
  • Lynx1 Capital Management first reported a position in Whitehawk Therapeutics in Q4 2022 and held it in 1 quarter.
  • Lynx1 Capital Management's Whitehawk Therapeutics position peaked at $831K in Q4 2022.
  • 70 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2023.

Based on Lynx1 Capital Management's 13F filing for Q1 2023, filed 15 May 2023.